Table 1:
Patient characteristics
| Characteristic | Pre-LTV N=376 |
Post-LTV N=362a |
|---|---|---|
| Demographics | ||
| Age in years, median (IQR) | 56.4 (44.5, 64.8) | 56.7 (42.4, 65.2) |
| Female sex | 175 (46.5) | 169 (46.7) |
| Race | ||
| Asian | 42 (11.2) | 35 (9.7) |
| Black | 10 (2.7) | 8 (2.2) |
| Other | 18 (4.8) | 18 (5.0) |
| White | 277 (73.7) | 277 (76.5) |
| Unknown | 29 (7.7) | 24 (6.6) |
| Underlying disease | ||
| Acute leukemia | 197 (52.4) | 195 (53.9) |
| Myelodysplastic syndrome | 94 (25.0) | 98 (27.1) |
| Aplastic Anemia | 15 (4.0) | 15 (4.1) |
| Chronic leukemia | 31 (8.2) | 29 (8.0) |
| Lymphoma | 21 (5.6) | 8 (2.2) |
| Plasma cell disorders | 14 (3.7) | 10 (2.8) |
| Otherb | 4 (1.1) | 7 (1.9) |
| Cytomegalovirus serostatus | ||
| Donor negative, recipient positive | 203 (54.0) | 193 (53.3) |
| Donor positive, recipient positive | 173 (46.0) | 169 (46.7) |
| HLA match and donor relation | ||
| Matched related | 90 (23.9) | 68 (18.8) |
| Matched unrelated | 186 (49.5) | 197 (54.4) |
| Mismatched related | 26 (6.9) | 29 (8.0) |
| Mismatched unrelatedc | 74 (19.7) | 68 (18.8) |
| Cell source | ||
| Umbilical cord blood | 42 (11.2) | 39 (10.8) |
| Bone marrow/peripheral blood | 334 (88.8) | 323 (89.2) |
| Conditioning regimen | ||
| Myeloablatived | 124 (33.0) | 126 (34.8) |
| GVHD prophylaxis e | ||
| PTCy regimen | 39 (10.4) | 77 (21.3) |
| Non-PTCy regimen | 337 (89.6) | 285 (78.7) |
| Cyclosporine + MMF +/− other | 143 (38.0) | 127 (35.1) |
| Cyclosporine + methotrexate | 7 (1.9) | 19 (5.3) |
| Tacrolimus + MMF +/− other | 52 (13.8) | 29 (8.0) |
| Tacrolimus + methotrexate +/− other | 130 (34.6) | 109 (30.1) |
| Otherf | 5 (1.3) | 1 (0.3) |
| Acute GVHD grade | ||
| Grade 0–1 | 136 (36.2) | 130 (35.9) |
| Grade ≥2 | 240 (63.8) | 232 (64.1) |
Results are reported as number with percentage in parenthesis unless specified otherwise.
GVHD: graft-versus-host disease, HCT: hematopoietic cell transplant, HLA: human leukocyte antigen, IQR: interquartile range, LTV: letermovir, MMF: mycophenolate mofetil, PTCy: post-transplantation high-dose cyclophosphamide
35 patients in the post-LTV cohort did not receive LTV.
Other underlying diseases included: sickle cell anemia (n=2), immune deficiency disorder/disease or syndrome (n=3), chronic granulomatous disease (n=1), paroxysmal nocturnal hemoglobinuria (n=1), polycythemia vera (n=1), dyskeratosis congenita (n=1), familial hemophagocytic lymphistiocytosis (n=1), multiple sclerosis (n=1).
All HLA-mismatched related HCTs were haploidentical.
Myeloablative regimens included any regimen containing ≥800 cGY total body irradiation, any regimen containing carmustine/etoposide/cytarabine/melphalan (BEAM), or any regimen containing busulfan/cyclophosphamide with or without antithymocyte globulin.
Sirolimus was included in the GVHD prophylaxis regimen in combination with cyclophosphamide-containing regimen or a non-cyclophosphamide-containing regimen in 178 patients (24.1%): 59 (15.7%) in the pre-LTV cohort and 119 (32.9%) in the post-LTV cohort.
No prophylaxis in 1 patient (syngeneic HCT) in the post-LTV cohort and tacrolimus only prophylaxis in 5 patients in pre-LTV cohort.